Volume | 1,148,787 |
|
|||||
News | (2) | ||||||
Day High | 3.50 | Low High |
|||||
Day Low | 2.37 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Lixte Biotechnology Holdings Inc | LIXT | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
2.51 | 2.37 | 3.50 | 2.45 | 2.52 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
6,353 | 1,148,787 | US$ 2.89 | US$ 3,322,273 | - | 1.58 - 9.50 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:56:43 | formt | 118 | US$ 2.40 | USD |
Lixte Biotechnology Holdings Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
5.51M | 2.25M | - | 0 | -5.09M | -2.26 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Lixte Biotechnology News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical LIXT Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.42 | 3.50 | 2.05 | 2.32 | 20,006 | -0.02 | -0.83% |
1 Month | 2.45 | 3.50 | 2.05 | 2.49 | 29,405 | -0.05 | -2.04% |
3 Months | 2.24 | 4.40 | 2.05 | 3.49 | 587,430 | 0.16 | 7.14% |
6 Months | 2.05 | 4.40 | 1.69 | 3.41 | 291,895 | 0.35 | 17.07% |
1 Year | 5.15 | 9.50 | 1.58 | 3.80 | 192,672 | -2.75 | -53.40% |
3 Years | 30.50 | 49.50 | 1.58 | 17.39 | 717,283 | -28.10 | -92.13% |
5 Years | 38.50 | 71.90 | 1.58 | 21.69 | 705,381 | -36.10 | -93.77% |
Lixte Biotechnology Description
Lixte Biotech Holdings Inc is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. The company focuses on developing new treatments for human cancers for which therapies are urgently needed. It mainly designs drugs for which there are existing data suggesting any effect on altered pathways of the cancer cell and may be given safely to humans. The development program of the company includes drugs for the treatment of cancer, consisting of protein phosphatase inhibitors and histone deacetylase inhibitors. |